

**Table 41. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy (COT): Reporting Areas, 2008<sup>1</sup>**

Reporting Area	Total Cases	Therapy ≤1 Year Indicated <sup>2,3,4</sup>			Therapy >1 Year Indicated <sup>3,5</sup>		All Drug Therapy <sup>3</sup>	
		No.	COT ≤1 Year(%)	COT(%)	No.	COT(%)	No.	COT(%)
<b>United States</b>	<b>12,905</b>	<b>11371</b>	<b>(84.6)</b>	<b>(92.7)</b>	<b>291</b>	<b>(80.4)</b>	<b>11705</b>	<b>(92.0)</b>
Alabama	176	150	(90.0)	(94.0)	2	(100.0)	152	(94.1)
Alaska	50	45	(88.9)	(97.8)	0	...	45	(97.8)
Arizona	227	195	(72.8)	(79.5)	2	(50.0)	197	(79.2)
Arkansas	84	75	(76.0)	(88.0)	2	(100.0)	77	(88.3)
California	2,700	2390	(83.1)	(92.2)	69	(66.7)	2459	(91.5)
Colorado	103	94	(92.6)	(96.8)	4	(75.0)	98	(95.9)
Connecticut	98	88	(90.9)	(97.7)	4	(100.0)	92	(97.8)
Delaware	23	22	(81.8)	(90.9)	1	(0.0)	23	(87.0)
District of Columbia	54	49	(79.6)	(83.7)	1	(100.0)	50	(84.0)
Florida	957	826	(89.6)	(94.7)	16	(93.8)	842	(94.7)
Georgia	477	411	(86.1)	(91.2)	9	(55.6)	428	(88.8)
Hawaii	124	115	(76.5)	(93.0)	0	...	115	(93.0)
Idaho	11	11	(90.9)	(100.0)	0	...	11	(100.0)
Illinois	466	414	(84.5)	(93.2)	15	(100.0)	430	(93.3)
Indiana	118	102	(91.2)	(93.1)	1	(100.0)	103	(93.2)
Iowa	49	47	(89.4)	(93.6)	0	...	47	(93.6)
Kansas	57	54	(92.6)	(98.1)	1	(100.0)	55	(98.2)
Kentucky	101	88	(80.7)	(88.6)	1	(0.0)	89	(87.6)
Louisiana	227	210	(79.5)	(93.3)	0	...	210	(93.3)
Maine	9	8	--	--	1	--	9	--
Maryland	278	248	(89.1)	(94.4)	6	(100.0)	254	(94.5)
Massachusetts	261	235	(80.9)	(93.6)	5	(60.0)	240	(92.9)
Michigan	188	151	(80.1)	(92.1)	7	(85.7)	158	(91.8)
Minnesota	211	182	(89.6)	(95.1)	4	(100.0)	203	(87.2)
Mississippi	117	96	(92.7)	(97.9)	4	(75.0)	100	(97.0)
Missouri	107	100	(86.0)	(94.0)	2	(100.0)	102	(94.1)
Montana	9	5	(100.0)	(100.0)	0	...	5	(100.0)
Nebraska	33	30	(80.0)	(90.0)	0	...	30	(90.0)
Nevada	102	89	(83.1)	(91.0)	3	(100.0)	92	(91.3)
New Hampshire	19	17	(82.4)	(82.4)	0	...	17	(82.4)
New Jersey	422	379	(87.6)	(93.9)	11	(90.9)	390	(93.8)
New Mexico	60	48	(91.7)	(100.0)	2	(100.0)	50	(100.0)
New York State <sup>6</sup>	304	275	(85.8)	(94.9)	7	(100.0)	282	(95.0)
New York City	893	788	(88.1)	(94.9)	25	(80.0)	828	(92.8)
North Carolina	335	301	(90.0)	(97.0)	10	(90.0)	311	(96.8)
North Dakota	3	3	(33.3)	(33.3)	0	...	3	(33.3)
Ohio	213	189	(85.7)	(91.5)	5	(100.0)	194	(91.8)
Oklahoma	100	86	(76.7)	(86.0)	1	(100.0)	87	(86.2)
Oregon	75	70	(97.1)	(98.6)	1	(100.0)	71	(98.6)
Pennsylvania	387	343	(77.3)	(89.2)	8	(87.5)	353	(88.7)
Rhode Island	36	34	(85.3)	(100.0)	0	...	34	(100.0)
South Carolina	188	160	(85.0)	(93.8)	2	(100.0)	162	(93.8)
South Dakota	16	15	(93.3)	(100.0)	1	(100.0)	16	(100.0)
Tennessee	282	248	(86.7)	(94.4)	3	(66.7)	251	(94.0)
Texas	1,501	1304	(80.4)	(90.0)	42	(73.8)	1346	(89.5)
Utah	27	23	(95.7)	(95.7)	2	(100.0)	25	(96.0)
Vermont	6	5	(60.0)	(60.0)	0	...	5	(60.0)
Virginia	292	269	(83.6)	(91.4)	3	(100.0)	272	(91.5)
Washington	228	197	(90.4)	(97.5)	7	(85.7)	204	(97.1)
West Virginia	28	22	(95.5)	(100.0)	0	...	22	(100.0)
Wisconsin	68	60	(70.0)	(86.7)	1	(100.0)	61	(86.9)
Wyoming	5	5	(80.0)	(80.0)	0	...	5	(80.0)
American Samoa <sup>7</sup>	3	3	--	--	0	...	3	--
Fed. States of Micronesia <sup>7</sup>	182	157	--	--	1	--	165	--
Guam <sup>7</sup>	89	84	(92.9)	(97.6)	2	(100.0)	86	(97.7)
Marshall Islands <sup>7</sup>	128	115	(80.0)	(87.8)	2	(100.0)	120	(85.8)
N. Mariana Islands <sup>7</sup>	35	34	(70.6)	(82.4)	0	...	34	(82.4)
Puerto Rico <sup>7</sup>	95	69	(95.7)	(97.1)	1	(100.0)	70	(97.1)
Republic of Palau <sup>7</sup>	17	14	--	--	0	...	15	--
U.S. Virgin Islands <sup>7</sup>	4	4	(50.0)	(50.0)	(0.0)	...	4	(50.0)

<sup>1</sup>Most recent year for which data are available.

<sup>2</sup>Initial isolate susceptible to rifampin (n=8,543) or susceptibility unknown (n=155); culture negative (n=2,236); culture status unknown (n=437).

<sup>3</sup>Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed, who did not die during therapy. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for reporting areas with information reported for ≥90% of cases.

<sup>4</sup>Excludes initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or positive blood culture.

<sup>5</sup>Initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or positive blood culture.

<sup>6</sup>Excludes New York City.

<sup>7</sup>Not included in U.S. totals.

**Note:** Ellipses indicate data not available. See Technical Notes for description of Completion of Therapy calculation (page 9).